Yin Yang 1 promotes aggressive cell growth in high‐grade breast cancer by directly transactivating kinectin 1-Reference-Cited by-同舟云学术

Yin Yang 1 promotes aggressive cell growth in high‐grade breast cancer by directly transactivating kinectin 1

Published:2022-07-05 Issue:3 Volume:3 Page:
ISSN:2688-2663
Container-title:MedComm
language:en
Short-container-title:MedComm

Author:

Gao Lin¹,Zhou Wenbin²,Xie Ni³,Qiu Junying⁴,Huang Jingyi¹,Zhang Zhe¹,Hong Malin¹⁵,Xia Jinquan¹,Xu Jing¹,Zhao Pan¹⁵,Fu Li⁶,Luo Yuwei²,Jiang Jing⁷,Gong Hui⁷,Wang Jigang¹⁵,Dai Yong¹,Luo Dixian⁷,Zou Chang¹⁵⁸^ORCID

Affiliation:

1. Department of Clinical Medical Research Center The Second Clinical Medical College Jinan University (Shenzhen People's Hospital) The First Affiliated Hospital of Southern University of Science and Technology Shenzhen Guangdong China

2. Department of Thyroid and Breast Surgery Department of General Surgery The Second Clinical Medical College Jinan University (Shenzhen People's Hospital) The First Affiliated Hospital of Southern University of Science and Technology Shenzhen Guangdong China

3. Biobank Shenzhen Second People’ s Hospital Shenzhen, Health Science Center First Affiliated Hospital of Shenzhen University Shenzhen Guangdong China

4. Medical Laboratory of Shenzhen Luohu People's Hospital Shenzhen Guangdong China

5. Shenzhen Public Service Platform on Tumor Precision Medicine and Molecular Diagnosis the Second Clinical Medical College Jinan University Shenzhen Guangdong PR China

6. Guangdong Provincial Key Laboratory of Regional Immunity and Diseases Department of Pharmacology and International Cancer Center Shenzhen University Health Science Center Shenzhen Guangdong China

7. Department of Laboratory Medicine Huazhong University of Science and Technology Union Shenzhen Hospital (Nanshan Hospital) Shenzhen Guangdong China

8. School of Life and Health Sciences The Chinese University of Kong Hong Shenzhen Guangdong China

Publisher

Wiley

Subject

General Medicine

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/mco2.133

Reference44 articles.

1. Genomic and Transcriptomic Landscape of Triple-Negative Breast Cancers: Subtypes and Treatment Strategies

2. Paclitaxel with inhibitor of apoptosis antagonist, LCL161, for localized triple‐negative breast cancer, prospectively stratified by gene signature in a biomarker‐driven neoadjuvant trial;Bardia A;J Clin Oncol,2018

3. Comprehensive Transcriptome Profiling Reveals Multigene Signatures in Triple-Negative Breast Cancer

4. Breast Cancer Treatment

5. Kinectin-dependent Assembly of Translation Elongation Factor-1 Complex on Endoplasmic Reticulum Regulates Protein Synthesis

Cited by 1 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Transcription factor E2F8 is a therapeutic target in the basal-like subtype of breast cancer;Frontiers in Oncology;2023-02-06